{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:46:04Z","timestamp":1792190764277,"version":"4.4.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006507","name":"Funda\u00e7\u00e3o Oswaldo Cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019920","name":"Soci\u00e9t\u00e9 d'Acc\u00e9l\u00e9ration du Transfert de Technologies","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004586","name":"Funda\u00e7\u00e3o Carlos Chagas Filho de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004586","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Parasitology"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.exppara.2024.108787","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:21:27Z","timestamp":1715786487000},"page":"108787","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Activity of pyridyl-pyrazolone derivatives against Trypanosoma cruzi"],"prefix":"10.1016","volume":"262","author":[{"given":"Denise da Gama Jaen","family":"Batista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludmila Ferreira","family":"de Almeida Fiuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Klupsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krislayne Nunes","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Meuser","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketlym","family":"da Concei\u00e7\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassiba","family":"Bouafia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Vergoten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Millet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Thuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2973-9357","authenticated-orcid":false,"given":"Christian","family":"Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria de Nazar\u00e9 Correia","family":"Soeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exppara.2024.108787_bib1","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00152-21","article-title":"Worldwide control and management of Chagas disease in a new era of globalization: a close look at congenital trypanosoma cruzi infection","volume":"35","author":"Abras","year":"2022","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.exppara.2024.108787_bib2","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.exppara.2024.108787_bib3","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1016\/j.tetlet.2015.04.061","article-title":"Evaluation of pyrrolidine and pyrazolone derivatives as inhibitors of trypanosomal phosphodiesterase B1 (TbrPDEB1)","volume":"56","author":"Amata","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.exppara.2024.108787_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866120","article-title":"Role of the PD-1\/PD-L1 pathway in experimental Trypanosoma cruzi infection and potential therapeutic options","volume":"13","author":"Arana","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exppara.2024.108787_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.897133","article-title":"Immunization with lipopolysaccharide-activated dendritic cells generates a specific CD8+ T cell response that confers partial protection against infection with Trypanosoma cruzi","volume":"12","author":"Biscari","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.exppara.2024.108787_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/17460441.2018.1417380","article-title":"Phenotypic screening approaches for Chagas disease drug discovery","volume":"13","author":"Chatelain","year":"2018","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.exppara.2024.108787_bib7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/ph14010029","article-title":"Role of edaravone as a treatment option for patients with amyotrophic lateral sclerosis","volume":"14","author":"Cho","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.exppara.2024.108787_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.598943","article-title":"Leishmania parasites drive PD-L1 expression in mice and human neutrophils with suppressor capacity","volume":"12","author":"da Fonseca-Martins","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exppara.2024.108787_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56336-8","article-title":"Immunotherapy using anti-PD-1 and anti-PD-L1 in Leishmania amazonensis-infected BALB\/c mice reduce parasite load","volume":"9","author":"da Fonseca-Martins","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exppara.2024.108787_bib10","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/jac\/dkz516","article-title":"Evaluation of phthalazinone phosphodiesterase inhibitors with improved activity and selectivity against Trypanosoma cruzi","volume":"75","author":"de Ara\u00fajo","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.exppara.2024.108787_bib11","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1128\/AAC.00414-20","article-title":"Efficacy of novel pyrazolone phosphodiesterase inhibitors in experimental mouse models of trypanosoma cruzi","volume":"64","author":"de Ara\u00fajo","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2024.108787_bib12","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02156-18","article-title":"Imidazole derivatives as promising agents for the treatment of Chagas disease","volume":"63","author":"de Ara\u00fajo","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2024.108787_bib13","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760210501chgsb","article-title":"Comment on \"The translational challenge in Chagas disease drug development\" by Kratz et al","volume":"117","author":"De Rycker","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2024.108787_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41579-022-00777-y","article-title":"Anti-trypanosomatid drug discovery: progress and challenges","volume":"2","author":"De Rycker","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.exppara.2024.108787_bib15","series-title":"Drugs for Neglected Diseases Initiative","year":"2023"},{"key":"10.1016\/j.exppara.2024.108787_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/pim.12107","article-title":"Immunoregulatory networks in human Chagas disease","volume":"36","author":"Dutra","year":"2014","journal-title":"Parasite Immunol."},{"key":"10.1016\/j.exppara.2024.108787_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imm.13622","article-title":"Activation-induced marker assays for identification of Trypanosoma cruzi-specific CD4 or CD8 T cells in chronic Chagas disease patients","volume":"169","author":"Ferragut","year":"2023","journal-title":"Immunology"},{"key":"10.1016\/j.exppara.2024.108787_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejmech.2018.02.020","article-title":"Identification of Pyrazolo[3,4-e][1,4]thiazepin based CYP51 inhibitors as potential Chagas disease therapeutic alternative: in vitro and in vivo evaluation, binding mode prediction and SAR exploration","volume":"149","author":"Ferreira de Almeida Fiuza","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib19","doi-asserted-by":"crossref","first-page":"8087","DOI":"10.3390\/molecules27228087","article-title":"Phenotypic evaluation of nucleoside analogues against Trypanosoma cruzi infection: in vitro and in vivo approaches","volume":"27","author":"Fiuza","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2024.108787_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.104800","article-title":"Resveratrol impacts in oxidative stress in liver during Trypanosoma cruzi infection","volume":"153","author":"Fracasso","year":"2021","journal-title":"Microb. Pathog."},{"key":"10.1016\/j.exppara.2024.108787_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1017\/S0031182020000153","article-title":"Anti-inflammatory and antioxidant therapies for chagasic myocarditis: a systematic review","volume":"147","author":"Freitas","year":"2020","journal-title":"Parasitology"},{"key":"10.1016\/j.exppara.2024.108787_bib22","first-page":"1","article-title":"State-of-the-Art in the drug discovery pathway for Chagas disease: a framework for drug development and target validation","volume":"14","author":"Gabald\u00f3n-Figueira","year":"2023","journal-title":"Res. Rep. Trop. Med."},{"key":"10.1016\/j.exppara.2024.108787_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115766","article-title":"Identifying inhibitors of Trypanosoma cruzi nucleoside diphosphate kinase 1 as potential repurposed drugs for Chagas' disease","volume":"216","author":"Galceran","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.exppara.2024.108787_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.866179","article-title":"Exhausted PD-1+ TOX+ CD8+ T cells arise only in long-term experimental Trypanosoma cruzi infection","volume":"13","author":"G\u00e1lvez","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exppara.2024.108787_bib25","doi-asserted-by":"crossref","DOI":"10.1590\/0037-8682-0150-2019","article-title":"Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil","volume":"53","author":"Gontijo","year":"2020","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"10.1016\/j.exppara.2024.108787_bib26","doi-asserted-by":"crossref","first-page":"7564","DOI":"10.1128\/AAC.01294-15","article-title":"Different therapeutic outcomes of benznidazole and VNI treatments in different genders in mouse experimental models of trypanosoma cruzi infection","volume":"59","author":"Guedes-da-Silva","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.exppara.2024.108787_bib27","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1128\/IAI.01047-10","article-title":"Regulation of Trypanosoma cruzi-induced myocarditis by programmed death cell receptor 1","volume":"79","author":"Gutierrez","year":"2011","journal-title":"Infect. Immun."},{"key":"10.1016\/j.exppara.2024.108787_bib28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.2174\/1389557522666220930154527","article-title":"Small-molecule drugs in immunotherapy","volume":"23","author":"Hao","year":"2023","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib29","doi-asserted-by":"crossref","first-page":"17","DOI":"10.7326\/AITC202302210","article-title":"Chagas disease","volume":"176","author":"Hochberg","year":"2023","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.exppara.2024.108787_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155839","article-title":"The expression of PD-1 and its ligands increases in Leishmania infection and its blockade reduces the parasite burden","volume":"153","author":"Jafarzadeh","year":"2022","journal-title":"Cytokine"},{"key":"10.1016\/j.exppara.2024.108787_bib31","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/2159-8290.CD-21-1156","article-title":"Characterization of INCB086550: a potent and novel small-molecule PD-L1 inhibitor","volume":"12","author":"Koblish","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.exppara.2024.108787_bib32","doi-asserted-by":"crossref","first-page":"100","DOI":"10.2174\/1574892813666181029142812","article-title":"Novel small molecule inhibitors of programmed cell death (PD)-1, and its ligand, PD-L1 in cancer immunotherapy: a review update of patent literature. Recent pat","volume":"14","author":"Kopalli","year":"2019","journal-title":"Anticancer Drug Discov"},{"key":"10.1016\/j.exppara.2024.108787_bib33","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760200501","article-title":"The translational challenge in Chagas disease drug development","volume":"117","author":"Kratz","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2024.108787_bib34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14728222.2023.2264512","article-title":"Molecular targets for Chagas disease: validation, challenges and lead compounds for widely exploited targets","volume":"27","author":"Laureano de Souza","year":"2023","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.exppara.2024.108787_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114343","article-title":"Pyrazolones as inhibitors of immune checkpoint blocking the PD-1\/PD-L1 interaction","volume":"236","author":"Le Biannic","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib36","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.3390\/molecules27103316","article-title":"Antioxidant properties and aldehyde reactivity of PD-L1 targeted aryl-pyrazolone anticancer agents","volume":"27","author":"Leleu-Chavain","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2024.108787_bib37","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/1061186X.2018.1440400","article-title":"Development of small-molecule immune checkpoint inhibitors of PD-1\/PD-L1 as a new therapeutic strategy for tumour immunotherapy","volume":"27","author":"Li","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.exppara.2024.108787_bib38","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1021\/acs.jmedchem.1c00628","article-title":"Self-masked aldehyde inhibitors: a novel strategy for inhibiting cysteine proteases","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib39","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3390\/pathogens12020282","article-title":"A review on the immunological response against Trypanosoma cruzi","volume":"12","author":"Macaluso","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.exppara.2024.108787_bib40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17963-1","article-title":"PD-1\/PD-L1 binding studies using microscale thermophoresis","volume":"7","author":"Magnez","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exppara.2024.108787_bib41","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2147\/JEP.S267378","article-title":"Review on experimental treatment strategies against Trypanosoma cruzi","volume":"13","author":"Mazzeti","year":"2021","journal-title":"J. Exp. Pharmacol."},{"key":"10.1016\/j.exppara.2024.108787_bib42","first-page":"198","article-title":"Interaction of trypanosoma cruzi with heart muscle cells: ultrastructural and cytochemical analysis of endocytic vacuole formation and effect upon myogenesis in vitro","volume":"41","author":"Meirelles","year":"1986","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.exppara.2024.108787_bib43","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exppara.2024.108787_bib44","doi-asserted-by":"crossref","first-page":"8745","DOI":"10.1021\/jm301059b","article-title":"Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1","volume":"55","author":"Orrling","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib45","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41564-022-01211-y","article-title":"Discovery of an orally active benzoxaborole prodrug effective in the treatment of Chagas disease in non-human primates","volume":"7","author":"Padilla","year":"2022","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.exppara.2024.108787_bib46","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1080\/14737175.2023.2251687","article-title":"Oral edaravone - introducing a flexible treatment option for amyotrophic lateral sclerosis","volume":"23","author":"Pattee","year":"2023","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.exppara.2024.108787_bib47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13071-022-05581-4","article-title":"The pipeline for drugs for control and elimination of neglected tropical diseases: 1. Anti-infective drugs for regulatory registration","volume":"16","author":"Pfarr","year":"2023","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.exppara.2024.108787_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1233253","article-title":"Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities","volume":"14","author":"Porta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.exppara.2024.108787_bib49","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3390\/molecules28083491","article-title":"Novel PD-L1-targeted phenyl-pyrazolone derivatives with antioxidant properties","volume":"28","author":"Regnault","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.exppara.2024.108787_bib50","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1590\/S0074-02762010000200022","article-title":"In vitro and in vivo experimental models for drug screening and development for Chagas disease","volume":"105","author":"Romanha","year":"2010","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2024.108787_bib51","article-title":"Potential role of antioxidants as adjunctive therapy in Chagas disease","volume":"26","author":"S\u00e1nchez-Villamil","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.exppara.2024.108787_bib52","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760210401","article-title":"Antioxidant defence system as a rational target for Chagas disease and Leishmaniasis chemotherapy","volume":"117","author":"Santi","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2024.108787_bib53","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1017\/S0031182021002079","article-title":"Phenotypic investigation of 4-nitrophenylacetyl- and 4-nitro-1H-imidazoyl-based compounds as antileishmanial agents","volume":"149","author":"Santos","year":"2022","journal-title":"Parasitology"},{"key":"10.1016\/j.exppara.2024.108787_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2021.608438","article-title":"Structure activity relationship of N-substituted phenyldihydropyrazolones against Trypanosoma cruzi amastigotes","volume":"9","author":"Sijm","year":"2021","journal-title":"Front. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib55","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1002\/cmdc.201900370","article-title":"Identification of phenylpyrazolone dimers as a new class of anti-trypanosoma cruzi agents","volume":"14","author":"Sijm","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.exppara.2024.108787_bib56","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cmdc.202000136","article-title":"Structure-activity relationship of phenylpyrazolones against trypanosoma cruzi","volume":"15","author":"Sijm","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.exppara.2024.108787_bib57","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760220004","article-title":"Perspectives for a new drug candidate for Chagas disease therapy","volume":"117","author":"Soeiro","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.exppara.2024.108787_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.actatropica.2019.105273","article-title":"Intracellular cyclic AMP levels modulate differential adaptive responses on epimastigotes and cell culture trypomastigotes of Trypanosoma cruzi","volume":"202","author":"Sternlieb","year":"2020","journal-title":"Acta Trop."},{"key":"10.1016\/j.exppara.2024.108787_bib59","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pt.2023.03.015","article-title":"Effective drug discovery in Chagas disease","volume":"39","author":"Tarleton","year":"2023","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.exppara.2024.108787_bib60","unstructured":"Thuru, X., Quesnel, M., Magnez, R., Millet, R., Leleu, N., Klupsch, F. Novel Pyrazolone Derivatives as PD-1\/pd-L1 Interaction Inhibitors. EP3766544, PCT\/EP2020\/070478 (WO\/2021\/009384)."},{"key":"10.1016\/j.exppara.2024.108787_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000528499","article-title":"A potential off-target effect of the wnt\/\u03b2-catenin inhibitor KYA1797K: PD-L1 binding and checkpoint inhibition","volume":"8","author":"Thuru","year":"2023","journal-title":"Biomed. Hub"},{"key":"10.1016\/j.exppara.2024.108787_bib62","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.exppara.2024.108787_bib63","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/cid\/ciac579","article-title":"A phase 2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease","volume":"76","author":"Torrico","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.exppara.2024.108787_bib64","doi-asserted-by":"crossref","first-page":"11788","DOI":"10.1074\/jbc.M111.326777","article-title":"Biological and structural characterization of Trypanosoma cruzi phosphodiesterase C and Implications for design of parasite selective inhibitors","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.exppara.2024.108787_bib65","series-title":"Chagas Disease","year":"2023"},{"key":"10.1016\/j.exppara.2024.108787_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.867928","article-title":"Self-masked aldehyde inhibitors of human cathepsin L are potent anti-CoV-2 agents","volume":"10","author":"Zhu","year":"2022","journal-title":"Front. Chem."}],"container-title":["Experimental Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489424000900?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014489424000900?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T22:25:28Z","timestamp":1718231128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014489424000900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":66,"alternative-id":["S0014489424000900"],"URL":"https:\/\/doi.org\/10.1016\/j.exppara.2024.108787","relation":{},"ISSN":["0014-4894"],"issn-type":[{"value":"0014-4894","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of pyridyl-pyrazolone derivatives against Trypanosoma cruzi","name":"articletitle","label":"Article Title"},{"value":"Experimental Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exppara.2024.108787","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108787"}}